[Update on hepatorenal syndrome].
The hepatorenal syndrome is a form of renal failure occurring in patients with advanced liver disease. The diagnosis is based both on the demonstration of low GFR and exclusion of other common causes of renal failure that may occur in patients with cirrhosis. Orthotopic liver transplantation remains the only curative treatment for this poor outcome disease; other modalities such as vasopressin analogues, transjugular intrahepatic portosystemic shunt or renal replacement therapies may serve as a bridge to transplantation. This article reviews the pathophysiology, diagnosis and current treatment of hepatorenal syndrome.
Blaise
P
P
Service de néphrologie, CHU Sart-Tilman, Liège.
Moonen
Martial
M
Rorive
G
G
D058186:Acute Kidney Injury / Q000139:chemically induced / Q000175:diagnosis; D003404:Creatinine / Q000097:blood; D003937:Diagnosis, Differential; D004487:Edema / Q000209:etiology; D005919:Glomerular Filtration Rate; D006530:Hepatorenal Syndrome / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology / Q000601:surgery; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications / Q000503:physiopathology; D016031:Liver Transplantation; D010536:Peritoneovenous Shunt; D011170:Portasystemic Shunt, Surgical; D012079:Renal Circulation / Q000187:drug effects; D017582:Renal Replacement Therapy; D012084:Renin-Angiotensin System / Q000502:physiology; D012709:Serum Albumin / Q000172:deficiency; D013152:Splanchnic Circulation / Q000187:drug effects; D014662:Vasoconstrictor Agents / Q000494:pharmacology / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000494:pharmacology / Q000627:therapeutic use; D014667:Vasopressins / Q000378:metabolism; D014883:Water-Electrolyte Imbalance / Q000209:etiology
D012709:Serum Albumin; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D014667:Vasopressins; D003404:Creatinine